^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 847325

    i
    Other names: BI 847325
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim
    Drug class:
    MEK inhibitor, MEK1 inhibitor, MEK2 inhibitor, Aurora kinase A inhibitor, Aurora kinase inhibitor, Aurora kinase B inhibitor, Aurora kinase C inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    High in vitro and in vivo activity of BI-847325, a dual MEK/Aurora kinase inhibitor, in human solid and hematologic cancer models. (PubMed, Cancer Res Commun)
    BI-847325 showed a broader range of activity than the MEK inhibitor GDC-0623. In conclusion, dual MEK/Aurora kinase inhibition shows remarkable potential for treating multiple types of hematological and solid tumors. The combination with capecitabine was synergistic in colorectal, gastric, and mammary cancer.
    Preclinical • Journal
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    BRAF mutation • NRAS mutation
    |
    capecitabine • BI 847325 • GDC-0623
    almost2years
    BI-847325, a selective dual MEK and Aurora kinases inhibitor, reduces aggressive behavior of anaplastic thyroid carcinoma on an in vitro three-dimensional culture. (PubMed, Cancer Cell Int)
    The results of the present study suggest that BI-857,325 might be an effective multi-targeted anticancer drug for ATC treatment.
    Preclinical • Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • AURKA (Aurora kinase A) • AURKB (Aurora Kinase B) • ANXA5 (Annexin A5)
    |
    VEGFA expression
    |
    BI 847325
    over2years
    GANT61/BI-847325 combination: a new hope in lung cancer treatment. (PubMed, Med Oncol)
    To the best of our knowledge, the antitumor effects of BI-847325/GANT61 combination have not been tested before. Further in-vitro and in-vivo studies are warranted to support the findings.
    Journal • IO biomarker
    |
    mTOR (Mechanistic target of rapamycin kinase) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • GLI1 (GLI Family Zinc Finger 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    |
    BI 847325